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This study was conducted to assess the efficacy, safety, and
immunogenicity of canakinumab administered as a sub-
cutaneous injection to patients with CAPS. Herein we
report the results of 5 children (4–13 years) and 2 adoles-
cents (16 and 17 years) enrolled in the study. All had doc-
umented NALP-3 gene mutations. Entry criteria were
active disease evaluated by moderate to severe symptoms
of CAPS (based on a 5 point global physician's assessment
scale) and/or elevated CRP and SAA levels. The children
received canakinumab 2 mg/kg, while the 2 adolescents
received a dose of 150 mg. Subsequent injections were
administered after each relapse. Clinical remission was
defined as: physicians global assessment of disease activ-
ity absent/minimal, assessment of skin disease absent/
minimal, normal serum SAA and CRP levels. Canakinu-
mab improved symptoms in the majority of patients
within 1 day, with full clinical remission within 7 days.
Two children received subsequent additional intravenous
injections (5 mg/kg) to achieve a complete response. The
median time to re-dosing due to relapse was 88 days (n =
6) and 63 days (n = 5) after the first and second dose of
canakinumab respectively. One patient was discontinued
70 days after the first dose due to pregnancy. Injections
were well tolerated and so far no immunogenicity devel-
oped. The total exposure time ranged from 70 to 383 days.
Adverse events (AE) were mainly upper respiratory tract
infections. One serious AE was reported (vertigo). In con-
clusion, canakinumab was well tolerated and provided
long-lasting complete clinical remission in children with
CAPS.
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